0000950170-24-134240.txt : 20241206 0000950170-24-134240.hdr.sgml : 20241206 20241206180105 ACCESSION NUMBER: 0000950170-24-134240 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241204 FILED AS OF DATE: 20241206 DATE AS OF CHANGE: 20241206 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mates Sharon CENTRAL INDEX KEY: 0001585699 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 241533441 MAIL ADDRESS: STREET 1: C/O INTRA-CELLULAR THERAPIES, INC. STREET 2: 135 ROUTE 202/206 CITY: BEDMINSTER STATE: NJ ZIP: 07921 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 135 ROUTE 202/206 STREET 2: SUITE 6 CITY: BEDMINSTER STATE: NJ ZIP: 07921 BUSINESS PHONE: (646) 440-9333 MAIL ADDRESS: STREET 1: 135 ROUTE 202/206 STREET 2: SUITE 6 CITY: BEDMINSTER STATE: NJ ZIP: 07921 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 4 1 ownership.xml 4 X0508 4 2024-12-04 0001567514 Intra-Cellular Therapies, Inc. ITCI 0001585699 Mates Sharon C/O INTRA-CELLULAR THERAPIES, INC. 135 ROUTE 202/206, SUITE 6 BEDMINSTER NJ 07921 true true false false Chairman and CEO true Common Stock 2024-12-04 4 M false 51000 12.73 A 1121329 D Common Stock 2024-12-04 4 S false 27667 85.6222 D 1093662 D Common Stock 2024-12-04 4 S false 23333 86.0048 D 1070329 D Common Stock 2024-12-05 4 M false 51697 12.73 A 1122026 D Common Stock 2024-12-05 4 S false 50163 84.0645 D 1071863 D Common Stock 2024-12-05 4 S false 1534 84.6897 D 1070329 D Stock Option (right to buy) 12.73 2024-12-04 4 M false 51000 0 D 2029-01-07 Common Stock 51000 51697 D Stock Option (right to buy) 12.73 2024-12-05 4 M false 51697 0 D 2029-01-07 Common Stock 51697 0 D This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 3, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.91 to $85.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.91 to $86.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.52 to $84.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.56 to $85.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. All shares underlying this option have vested. /s/ John P. Condon, Attorney-in-fact 2024-12-06